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Grade of chronic renal failure, and acute and long-term out- ous coronary interventions (PCIs). Some recent reports
come after percutaneous coronary interventions. demonstrated that after PCI patients with moderate
Background. Patients with moderate chronic renal failure chronic renal failure also have a significantly higher riskhave recently been identified to suffer from a markedly higher
for cardiovascular complications or death compared tomortality after percutaneous coronary intervention (PCI). We
patients with normal renal function [1–5]. Moreover, thisfocused on the outcome of PCI patients with just mildly ele-
vated creatinine levels of 1.1 to 1.5 mg/dL. was shown for patients with creatinine levels of only 1.6
Methods. Data of all PCI patients of the years 1998 to 1999 to 2.0 mg/dL [2, 6, 7]. Due to the high number of patients
were analyzed. Follow-up was performed by a questionnaire with chronic renal failure, which is expected to rise fur-sent to all patients.
ther [8], a possible threshold above which an increase inResults. During this period, PCI was performed in 1049 pa-
cardiovascular risk could be observed is of interest. Ourtients. Long-term follow-up (1184  10 days) was 99.6% com-
plete. Total mortality increased continuously by each creatinine current study, therefore, analyzed the impact of creati-
increment of 0.1 mg/dL above 1.0 mg/dL, with a significant nine levels between 1.0 to 1.5 mg/dL on the acute and
difference at 1.3 mg/dL compared to patients with1.0 mg/dL
long-term outcome of patients after PCI.(12.4 vs. 5.5%, P  0.05). In a Kaplan-Meier model, patients
with a creatinine of 1.3 to 1.4 mg/dL had a significantly lower
cumulative survival after three years (87%) than controls (96%,
METHODSP 0.0108, log rank test). Higher serum creatinine levels were
found to be significantly associated with death in univariate Patients
analysis (1.1  0.4 vs. 1.5  1.0 mg/dL, P  0.00001), and in
All patients who underwent PCI from March 1, 1998multivariate analysis by stepwise logistic regression (OR 2.122,
to December 31, 1999 were identified from a computer95% CI 1.585 to 2.841).
Conclusions. In this retrospective cross-sectional study, even database in which the data of all patients who undergo
patients with slightly elevated serum creatinine levels of 1.3 to heart catheterization at our institution are stored [3]. In
1.4 mg/dL had a significantly reduced long-term outcome after
this database, apart from information about the interven-PCI. Thus, even mild chronic renal failure appears to be associ-
tion, more complete data about concomitant diseasesated with markedly increased risk after a PCI, with implications
to the high number of patients concerned. and some laboratory parameters such as creatinine val-
ues have been stored since March 1, 1998.
Follow-upPatients with end-stage renal failure on maintenance
A questionnaire developed in accordance with similarhemodialysis are known to have a markedly increased
studies was sent to all patients [1]. If the patients did notcardiovascular morbidity and mortality after percutane-
return their questionnaire, a follow-up was performed
by telephone calls with the patients, their relatives or
1 Drs. Reinecke and Trey contributed equally to this study. referring physicians.
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Table 1. Basic clinical data
Creatinine levels mg/dL
1.0 1.1–1.2 1.3–1.4 1.5–2.0 2.0
Patients in group N (% of total) 437 (41.7) 386 (36.8) 132 (12.6) 55 (5.2) 39 (3.7)
Age meanSD, years 62.610.4 63.49.8 63.69.8 63.412.9 63.49.5
Women N (%) 141 (32.3) 63 (16.3)c 15 (11.4)c 6 (11.3)b 5 (12.8)b
Hypertension N (%) 188 (43.0) 175 (45.2) 67 (50.8) 17 (31.5) 24 (60.0)a
Hyperlipidemia N (%) 206 (47.1) 214 (55.3) 75 (56.4) 22 (40.7) 22 (56.4)
History of smoking N (%) 166 (38.0) 136 (35.1) 44 (33.1) 28 (51.8) 14 (35.0)
Family history of cardiovascular disease N (%) 112 (25.6) 73 (18.9)a 36 (27.3) 10 (18.9) 6 (15.4)
Diabetes N (%) 56 (12.8) 69 (17.8)a 18 (13.6) 10 (18.5) 5 (12.5)
Patients with
1 vessel disease 43.2 38.0 37.9 30.2b 32.5
2 vessel diseases 31.4 35.4 40.9 28.3 32.5
3 vessel diseases 25.4 26.6 21.2 41.5 35.0
Previous myocardial infarction N (%) 173 (39.6) 132 (34.2) 54 (40.9) 17 (32.1) 12 (31.6)
Previous PCI N (%) 76 (17.4) 72 (18.7) 26 (19.7) 10 (18.9) 8 (20.0)
Previous CABG N (%) 57 (13.0) 50 (13.0) 17 (12.9) 5 (9.4) 5 (12.8)a
NYHA class meanSD 1.520.94 1.650.96a 1.760.85b 1.351.18 1.841.18a
Abbreviations are: CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention. All data are adjusted for age and previous bypass grafting.
Values differing significantly from those of the group with a creatinine of 1.0 mg/dL were marked as follows: a P  0.05; b P  0.01; c P  0.001.
the beginning of the procedure. The coronary segment, eign patients who returned to their home countries
the type of coronary stenosis dilated, and angiographic (99.6% complete). Three of these lost patients had a
success were classified in accordance to the revised classi- creatinine 1.0 mg/dL and one patient had a creatinine
fication of the American Heart Association and Ameri- of 1.1 mg/dL.
can College of Cardiology [9]. Angiographic success after The remaining 1049 patients were divided in subgroups
PCI was assumed if a residual stenosis in the vessel diam- depending on their baseline serum creatinine level be-
eter of 50% could be achieved in accordance to others fore PCI. Their basic clinical characteristics are summa-
[1, 7, 9]. Left ventricular ejection fraction (EF) was as- rized in Table 1. Creatinine values ranged between 0.7
sessed from the pre-PCI angiogram and determined from and 4.8 mg/dL. Significant differences were found re-
30 right anterior oblique (RAO) projections. Since some garding a higher age and a higher proportion of previous
PCIs were performed after coronary angiographies in coronary bypass grafting (CABG) in the patients with
external catheterization laboratories, the EF was only higher creatinine values. Therefore, all data were ad-
available in 54.8% of the patients. justed for age and CABG. The proportion of women
Creatinine values were determined with the standard decreased significantly with increasing creatinine levels.
procedure by Jaffe. Regarding classical cardiovascular risk factors, after an
adjustment for age and CABG, no significant differencesStatistical analyses
were found except for a higher frequency of hyperten-
Statistical tests were performed with SPSS 10.0 for sion in the subgroup with a creatinine of 2.0 mg/dL.
Windows (license number 7321214; SPSS, Chicago, IL,
USA). Univariate analyses were made using the Student Angiographic data and PCI performance
t test for continuous variables with normal distribution Data of the coronary status and left ventricular func-
(displayed as means  SD), cross tables with the chi- tion as well as procedural data of the PCI is displayed
square-test for dichotomous variables, and the non-para- in Table 2. The number of patients with unstable angina
metric Mann-Whitney rank sum test for categorical vari- or acute myocardial infarction at PCI was significantly
ables. Multivariate analysis was performed by logistic
higher in the patients with a creatinine of 1.0 mg/dL
regression analyses with a stepwise backward algorithm
than in those with higher creatinine levels. Stent useaccording to the method of Wald.
in patients with a creatinine of 1.5 to 2.0 mg/dL was
significantly lower than in the other groups. With regard
RESULTS to the modified classification of coronary stenoses in the
stent era in low, moderate and high risk lesions [9], aDuring these 22 months, a total of 1104 patients under-
continuous but not significant trend toward an increasewent 1440 PCI procedures. Patients with end-stage renal
of high risk lesions in patients with advanced renal failurefailure requiring maintenance hemodialysis or patients
could be observed. The angiographic success rate afterwith a history of previous hemodialysis (N  51) were
PCI was not significantly different between the severalexcluded from this analysis. A follow-up of the re-
maining 1053 patients was complete except for four for- creatinine subgroups.
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Table 2. PCI data
Creatinine levels mg/dL
1.0 1.1–1.2 1.3–1.4 1.5–2.0 2.0
Unstable angina or acute MI at presentation N (%) 82 (18.8) 38 (9.8)d 10 (7.6)c 7 (13.0) 5 (12.8)
Left ventricular ejection fraction meanSD % 6615 6518 6021 5915 7023
Diagnostic angiography and PCI in once (prima vista PCI) N (%) 235 (53.8) 185 (47.8) 48 (36.1) 33 (62.3) 19 (48.7)
PCI
1 segment % 69.6 71.0 69.0 67.3 69.2
2 segments % 26.1 21.8 22.5 20.0 25.6
3 segments % 3.2 6.0 7.0 9.1 5.2
4 segments % 1.1 1.2 1.5 3.6 0
Low risk lesiona N (%) 72 (16.5) 59 (15.3) 15 (11.4) 12 (22.6) 6 (15.8)
Moderate risk lesiona N (%) 284 (65.0) 250 (64.8) 89 (67.4) 28 (52.8) 21 (55.3)
High risk lesiona N (%) 81 (18.5) 77 (19.9) 28 (21.2) 13 (24.5) 11 (28.9)
Stent use N (%) 214 (49.0) 184 (47.5) 60 (45.5) 19 (35.8)b 19 (48.7)
Use of glycoprotein IIb/IIIa-inhibitors N (%) 39 (8.9) 24 (6.2) 8 (6.1) 4 (7.5) 3 (7.7)
Angiographic successa (residual stenosis 50%) N (%) 379 (86.7) 347 (89.9) 129 (90.8) 46 (83.6) 33 (84.6)
Abbreviations are: CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention. All data are adjusted for age and
previous bypass grafting.
a According to [9]: Smith SC, Dove JT, Jacobs AK, et al: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines).
J Am Coll Cardiol 37:2239I–2239LXVI, 2001
b P  0.05; c P  0.01; d P  0.001, values differing significantly from those of the group with a creatinine of 1.0 mg/dL
Table 3. Acute and long-term outcome after PCI
Creatinine levels mg/dL
1.0 1.1–1.2 1.3–1.4 1.5–2.0 2.0
Patients in group N (% of total) 437 (41.7) 386 (36.8) 132 (12.6) 55 (5.2) 39 (3.7)
30-day mortality N (%) 5 (1.1) 7 (1.8) 1 (0.8) 6 (11.1)b 4 (10.3)b
Follow-up time medianSD, days 703251 712258 740259 601317 567329
Death during follow-up N (%) 24 (5.5) 30 (7.8) 16 (12.1)a 14 (25.5)b 12 (30.8)b
Cardiac cause % of deaths 16 (66.7) 23 (76.7) 11 (68.8) 13 (92.9) 10 (83.4)
Cancer % of deaths 3 (12.5) 1 (3.3) 1 (6.3) 0 0
Others % of deaths 2 (8.3) 3 (10.0) 1 (6.3) 1 (7.1) 1 (8.3)
Unknown % of deaths 3 (12.5) 3 (10.0) 3 (18.8) 0 1 (8.3)
Non-fatal myocardial infarction N (%) 23 (5.6) 18 (5.1) 3 (2.6) 2 (5.3) 1 (3.6)
Death or non-fatal MI during follow-up N (%) 47 (10.8) 48 (12.4) 18 (13.5) 17 (32.1)b 12 (30.8)b
Repeat PCI N (%) 142 (34.1) 117 (32.5) 43 (35.2) 18 (42.9) 15 (48.4)
CABG after index PCI N (%) 31 (7.1) 18 (4.7) 13 (9.8) 1 (1.9) 1 (2.6)
PCI or CABG during follow-up N (%) 157 (35.9) 128 (33.2) 58 (40.8) 20 (36.4) 16 (41.0)
NYHA class meanSD 2.120.92 2.120.97 2.130.96 2.560.85a 2.401.01
Abbreviations are: CABG, coronary artery bypass grafting; NYHA, New York Heart Association classification of heart failure; PCI, percutaneous coronary
intervention. All data are adjusted for age and previous bypass grafting, except the number of deaths.
a P  0.05, b P  0.001, values differ significantly from those of the group with a creatinine of 1.0 mg/dL
Acute and long-term outcome controls in the patients with 1.3, 1.5 to 2.0 and 2.0
mg/dL (Fig. 1).The 30-day mortality was identical in the subgroups
The referring physicians were contacted to gain insightwith creatinine levels between 1.0 to 1.4 mg/dL, but sig-
into the causes of death in non-surviving patients. Infor-nificantly higher in those with a creatinine of 1.5 to 2.0,
mation on the cause of death could be retrieved in 86 ofand 2.0 mg/dL (Table 3). The rate of in-hospital myo-
96 patients (89.6%) who died. According to other studies
cardial infarctions was low in all groups (1/1/1/0/1 pa-
[1], these causes were classified in cardiac (including myo-
tient). cardial infarction, congestive heart failure, and sudden car-
Total mortality during follow-up increased with higher diac death), cancer and other causes. There was a ten-
creatinine levels, with a significant difference starting at dency for the rate of cardiac deaths to increase with higher
creatinine levels of 1.3 to 1.4 mg/dL and higher (Table 3). creatinine levels, although these differences did not reach
A detailed analysis of the creatinine levels and related statistical significance (Table 3).
mortality showed that with each increase in creatinine The rate of non-fatal myocardial infarctions, repeat
of 0.1 mg/dL above 1.0 mg/dL, mortality also increased, PCIs and CABG during follow-up was not significantly
different between the subgroups.with a significant difference in mortality compared to
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creatinine while other parameters were removed from
the model (Table 5). A receiver operator characteristics
(ROC) curve of this model described an area under the
curve of 0.752 (95% CI, 0.698 to 0.806).
DISCUSSION
To our knowledge, this study is the first to analyze
the impact of high-normal or mildly increased serum
creatinine levels in patients undergoing PCI. Since recent
reports described that even patients with serum creati-
nine levels of 1.6 to 2.0 mg/dL have a markedly reduced
outcome after PCI [2, 7], it was the aim of this work to
focus on possible lower thresholds of creatinine levels
Fig. 1. Cumulative mortality (in %) was plotted for the several groups
for impaired outcome. In fact, there was an increase inof patients depending on their serum creatinine levels at the time of
percutaneous coronary interventions (PCI). Numbers at the top of each total mortality by each step of 0.1 mg/dL above a creati-
bar denote the total number of patients in each group. There were nine of 1.0 mg/dL, while a significant difference to the
significant differences when the mortality of the patients with higher
mortality of patients with normal creatinine levels 1.0creatinine levels were compared to those with a creatinine of 1.0
mg/dL: *P  0.05; ***P  0.001. mg/dL was found at 1.3 mg/dL. A similar impact was
found on cumulative survival by a Kaplan-Meier model.
Although the value of creatinine as a marker of renal
function is limited by several factors, it could be easily
Furthermore, total mortality was compared for pa- accessed and is widely used in clinical routine. Therefore,
tients with and without multivessel disease. The mortal- we think that, despite the methodological limitations of
ity rates in patients with a creatinine of1.0 mg/dL were this parameter, our results do have implications for risk
8.5 versus 2.6% (P  0.011), with a creatinine of 1.3 to stratification of patients undergoing PCI: a creatinine of
1.4 mg/dL were 15.8 versus 2.0% (P  0.012), and with only 1.3 mg/dL, which in most patients indicates a re-
a creatinine of 1.5 mg/dL were 30% versus 25% (NS). duction in renal function of about 50%, is associated
The cumulative survival was analyzed using a Kaplan- with a twofold increased total mortality and a 10% reduc-
Meier model (Fig. 2). Compared to control patients with tion in cumulative survival over three years.
creatinine values 1.0 mg/dL, patients with a creatinine Comparing our patients’ characteristics and outcome
of 1.1 to 1.2 mg/dL did not have a significantly different with those examined in other studies, the epidemiologic
survival (P  0.197); however, patients with a creatinine data showed good accordance, especially with age, pro-
of 1.3 to 1.4 mg/dL (P  0.0108), 1.5 to 2.0 mg/dL (P  portion of women, coronary and left ventricular status
0.0001), and 2.0 mg/dL (P  0.0001, log rank test) as well as angiographic success rates [1, 2, 5]. Cumulative
showed a significantly reduced cumulative survival. survival rates in groups with creatinine levels of 1.5 to
2.0 and 2.0 mg/day, which could be compared directly
Factors associated with mortality to the results of the other studies [1, 7], were also very
Results of a univariate analysis of the patients’ and similar at about only 75% and 63%, respectively. The
procedural factors associated with death are summarized frequency of stent implantation as well as the observed
in Table 4. Apart from some patient characteristics such association with a lower mortality in patients who re-
as age, higher number of diseased vessels and reduced ceived stents was consistent with the findings of other
left ventricular function, some procedural risk indicators investigators [1].
such as the duration of PCI and amount of contrast dye Apart from the survival benefit by the use of, for ex-
used also differed significantly between surviving pa- ample, angiotensin receptor blockers or other drugs in
tients and those who died. Moreover, there was a signifi- patients with chronic renal failure [10, 11], an optimal
cant difference regarding the use of coronary stents. In strategy of revascularization in patients with renal failure
subgroup analyses, the benefit from stenting was simi- remains to be clarified. Whereas the mortality of patients
larly found in all groups, with a non-significant trend without multivessel disease in our study was very similar,
toward a greater benefit in the patients with higher cre- with 2.6% and 2.0% between those with a creatinine of
atinine levels. 1.0 mg/dL and those with values of 1.3 to 1.4 mg/dL,
A multivariate analysis using stepwise backward logis- the higher mortality in patients with a creatinine of 1.3 to
tic regression of the factors found to be significantly as- 1.4 mg/dL was especially due to the worse outcome of
sociated with death in the univariate analysis identified patients with multivessel disease. Above a creatinine of
1.5 mg/dL, the presence of multivessel disease did notindependent predictors of mortality including serum
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Fig. 2. Cumulative survival rate according to
the strata of creatinine levels of the patients
in a Kaplan-Meier model. Each cross repre-
sents a patient still alive during follow-up. The
cumulative survival of the patients with a cre-
atinine of1.0 mg/dL and that of the patients
with an elevated creatinine of 1.3 to 1.4 mg/dL
(P  0.0108, log rank test), 1.5 to 2.0 mg/dL
(P  0.001) and 2.0 mg/dL (P  0.001) was
found to be significantly different.
Table 4. Factors associated with death in univariate analysis
Survivors Non-survivors P value
Age meanSD, years 62.910.1 65.910.2 0.006
Women N (%) 216 (22.7) 16 (16.7) NS
Patients with unstable angina or acute MI N (%) 127 (13.3) 16 (16.7) NS
Number of diseased vessels meanSD 1.991.25 2.481.23 0.0002
Left ventricular ejection fraction meanSD, % 6616 5526 0.02
Diabetes N (%) 146 (15.2) 21 (21.9) NS
Patients with previous PCIs N (%) 184 (19.3) 9 (9.4) 0.017
Patients with previous CABG N (%) 116 (12.2) 20 (20.8) 0.016
Patients with stent implantation N (%) 466 (48.9) 35 (36.5) 0.013
Duration of PCI meanSD, minutes 69.535.4 88.246.9 0.00002
X-ray duration meanSD, seconds 11571628 15331117 0.027
Contrast dye meanSD, mL 247109 289119 0.0004
Serum creatinine levels meanSD, mg/dL 1.10.4 1.51.0 0.00001
Abbreviations are: CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Table 5. Logistic regression analysis of factors associated with death which patients may benefit from which strategy of revas-
cularization. The implications of these findings, especiallyP value Odds ratio 95% CI
if our results of the impact of even mildly elevated creati-Numbers of diseased vessels 0.00001 2.204 1.640 to 2.962
Serum creatinine levels 0.00001 2.122 1.585 to 2.841 nine levels would be confirmed, might be extensive due
Age 0.047 1.024 1.003 to 1.048 to the large number of patients concerned.
Stent implantation 0.020 0.579 0.365 to 0.918
What might be the reasons for the higher mortality?Patients with previous PCIs 0.005 0.349 0.168 to 0.723
Constant 0.00001 0.002 Taking the causes of death into account, there is some
evidence that higher creatinine levels were especially as-Further parameters which were initially included in the model were gender,
diabetes and previous bypass grafting, but these were stepwise removed by the sociated with an increase in cardiac deaths and, there-
alogorithm.
fore, it may not be just an indicator of the higher general
morbidity of these patients, including cancer or other
relevant comorbidities. However, since this study was
performed on a retrospective cross-sectional basis, no in-significantly affect the difference in the already high mor-
formation could be derived from the therapeutic ap-tality rates of 25 to 30% of these patients. Since there
proaches, the pathophysiologic background of the associ-is increasing evidence that at least patients with advanced
ation between serum creatinine and mortality, or whetherrenal failure benefit more from operative revasculariza-
renal failure is merely a risk indicator rather than a risktion than from an interventional approach [12–15], fur-
ther randomized studies are recommended to determine factor as stated by other authors [16]. The decrease in
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